Top

Investigational New Drugs

Published in:

01-05-2000

Cdc25 as a Potential Target of Anticancer Agents

Author: Jens W. Eckstein

Published in: Investigational New Drugs | Issue 2/2000

Title: Cdc25 as a Potential Target of Anticancer Agents
Author: Jens W. Eckstein
Publication date: 01-05-2000
Publisher: Kluwer Academic Publishers
Published in: Investigational New Drugs / Issue 2/2000
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI: https://doi.org/10.1023/A:1006377913494

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Please log in to get access to this content

Other articles of this Issue 2/2000

Chemotherapy in Non-Small Cell Lung Cancer

DNA G-Quadruplexes, Telomere-Specific Proteins and Telomere-Associated Enzymes as Potential Targets for New Anticancer Drugs

A Phase II Pilot Study of KW-2189 in Patients with Advanced Renal Cell Carcinoma

Cytotoxic Effects of Topotecan Combined with Various Active G2/M-Phase Anticancer Drugs in Human Tumor-Derived Cell Lines

A Phase II Trial of Topotecan in Esophageal Carcinoma: A Southwest Oncology Group Study (SWOG 9339)

UCN-01 Enhances the In Vitro Toxicity of Clinical Agents in Human Tumor Cell Lines

Keynote webinar | Spotlight on antibody–drug conjugates in cancer